Evidence map›Paper›PMID 29747694›Full record

SynthesisJournal of translational medicine2018

Clinical performance of stem cell therapy in patients with acute-on-chronic liver failure: a systematic review and meta-analysis.

Ran Xue, Qinghua Meng, Jinling Dong, Juan Li, Qinwei Yao, Yueke Zhu, Hongwei Yu

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04822922 (Safety of Human Umbilical Cord-derived Mesenchymal Stem Cell), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04822922 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Safety of Human Umbilical Cord-derived Mesenchymal Stem Cell (UC-MSC) Transfusion for Acute-on-chronic Liver Failure Patients

TypeinterventionalSponsorHai LiRan2021 to 2024Enrolled16ConditionsAcute-On-Chronic Liver FailureArmsHuman umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Stem cell-based therapy for human diseases.Signal transduction and targeted therapy · 2022
    Review
  11. [Current status, challenges and reflections on stem cell therapy for liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
  12. Review
  13. Article
  14. Observational
  15. [Advances in the study of mesenchymal stem cells for end-stage liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Review
  16. Review
  17. Review
  18. Review
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ran XueDepartment of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, No. 8, Xi tou tiao, You an men wai Street, Feng tai District, Beijing, 100069, People's Republic of China.
Qinghua MengDepartment of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, No. 8, Xi tou tiao, You an men wai Street, Feng tai District, Beijing, 100069, People's Republic of China. meng_qh@126.com.ORCID 0000-0001-9967-6403
Jinling DongDepartment of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, No. 8, Xi tou tiao, You an men wai Street, Feng tai District, Beijing, 100069, People's Republic of China.
Juan LiDepartment of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, No. 8, Xi tou tiao, You an men wai Street, Feng tai District, Beijing, 100069, People's Republic of China.
Qinwei YaoDepartment of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, No. 8, Xi tou tiao, You an men wai Street, Feng tai District, Beijing, 100069, People's Republic of China.
Yueke ZhuDepartment of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, No. 8, Xi tou tiao, You an men wai Street, Feng tai District, Beijing, 100069, People's Republic of China.
Hongwei YuDepartment of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, No. 8, Xi tou tiao, You an men wai Street, Feng tai District, Beijing, 100069, People's Republic of China.
Capital Medical University · CN

Funding

Capital Health Research and Development of Special 2011-2018-09the National Natural Science Foundation of China 81470877
6 · The paper itself

Abstract

backgroundStem cell therapy has been applied in the treatment of acute-on-chronic liver failure (ACLF). However, its clinical efficiency is still debatable. The aim of this systematic review and meta-analysis is to evaluate the clinical efficiency of stem cell therapy in the treatment of ACLF.

methodsThe Cochrane Library, OVID, EMBASE, and PUBMED were searched to December 2017. Both randomized and non-randomized studies, assessing stem cell therapy in patients with ACLF, were included. The outcome measures were total bilirubin (TBIL), alanine transaminase (ALT), international normalized ratio (INR), albumin (ALB), and the model for end-stage liver disease (MELD) score. The quality of evidence was assessed by GRADEpro.

resultsFour randomized controlled trials and six non-randomized controlled trials were included. The TBIL levels significantly decreased at 1-, 3-, 12-month after the stem cell therapy (p = 0.0008; p = 0.04; p = 0.007). The ALT levels decreased significantly compared with the control group in the short-term (p < 0.00001). There was no obvious change in the INR level compared with the control groups (p = 0.64). The ALB levels increased markedly as compared with the control groups (p < 0.0001). The significant difference can be found in MELD score between stem cell therapy and control groups (p = 0.008). Further subgroup analysis for 3-month clinical performance according to the stem cell types have also been performed.

conclusionThis study suggests that the clinical outcomes of stem cell therapy were satisfied in patients with ACLF in the short-term. MSCs may be better than BM-MNCs in the stem cells transplantation of ACLF. However, more attention should focus on clinical trials in large-volume centers.

Indexed as

Stem Cell TransplantationAcute-On-Chronic Liver FailureFollow-Up StudiesHumansLiverLiver Function TestsAcute-on-chronic liver failureClinical performanceStem cell therapy

Identifiers

PMID29747694
PMCPMC5946490
OpenAlexW2801398120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.